We need some news. Partnership would do nicely about right now. Something around $250M with some cash and nice milestones. What's nice is any deal on our ph2 drugs, ph3's right around the corner to reap milestone. I also believe we will hear something around the middle of the year that dacogen for aml breaks the 100M mark in sales in EU, triggering the $5M payout. Will they ever go after the Japan market and reach all the milestones on dacogen?
If they had anything the stock would be moving up by increments of $1.00 not by .01 cents.
They have to get an approval, a partnership won’t come on their “papers” and presentations, which may or may not be entirely valid.
We have heard these stories for years and years. Going on past references we have a good two years for a proper answer. I wish and hope not, but their past non-performance would suggest a slow movement.
Biotechs can surprise you at any moment. Sometimes bad and sometimes with a huge move. I believe we are closer to a breakout moment. We all understand Dr. M, he's conservative as they come, except with what goes in his pockets. But my point here, even before they announced the results from AT13387, they have gone ahead with two ph2's, they had to have a good feeling on what they were seeing, to move into two ph's 2's. Compare that with amuvatnib,
This company moved light years ahead in getting drugs that have the potential for approvals. We can sit here and listen to you tell us to wait and see or we can actually open our eyes. Your way we pay a premium, my way, we get shares for a steal. I'm not pointing out fluff developments, these are real. Maybe they are ph2 news, but if you wait for the whispers in your ear to load up, well THINK AGAIN. I don't have time for you rory. You are old news, with little to offer.
Why don't you do something useful and find a generic company working on dacogen. Then maybe your thoughts have merrits. Until, you just a guy in the wrong place at the wrong time.